Human umbilical cord blood mesenchymal stem cells as a potential therapy for schistosomal hepatic fibrosis: an experimental study

References

• Ghatak S, Biswas A, Dhali GK, et al. Oxidative stress and hepatic stellate cell activation are key events in arsenic induced liver fibrosis in mice. Toxicol Appl Pharmacol. 2011 Feb 15;251(1):59–69. PubMed PMID: 21134390; PubMed Central PMCID: PMCPMC3745774.
   PubMed Web of Science ®Google Scholar
• Perez HR, Stoeckle JH. Stuttering: clinical and research update. Can Fam Physician. 2016 Jun;62(6):479–484. PubMed PMID: 27303004; PubMed Central PMCID: PMCPMC4907555.
   PubMedGoogle Scholar
• Eom YW, Shim KY, Baik SK. Mesenchymal stem cell therapy for liver fibrosis. Korean J Intern Med. 2015Sep;30(5):580–589. PubMed PMID: 26354051; PubMed Central PMCID: PMCPMC4578027.
   PubMed Web of Science ®Google Scholar
• Oliveira SA, Souza BS, Guimaraes-Ferreira CA, et al. Therapy with bone marrow cells reduces liver alterations in mice chronically infected by Schistosoma mansoni. World J Gastroenterol. 2008 Oct 14;14(38):5842–5850. PubMed PMID: 18855983; PubMed Central PMCID: PMCPMC2751894.
   PubMed Web of Science ®Google Scholar
• Abou Rayia DM, Elmarhoumy SM, Ismail HH, et al. The outcomes of bone marrow stromal cell therapy in schistosomal hepatic fibrosis: an experimental study. J Egypt Soc Parasitol. 2017;47(3):633–642.
   Google Scholar
• Xiao SH, Mei JY, Jiao PY. Schistosoma japonicum-infected hamsters (Mesocricetus auratus) used as a model in experimental chemotherapy with praziquantel, artemether, and OZ compounds. Parasitol Res. 2011Feb;108(2):431–437. PubMed PMID: 20922422.
   PubMed Web of Science ®Google Scholar
• Abou-El-Naga IF. Schistosoma mansoni sarco/endoplasmic reticulum Ca(2+) ATPases (SERCA): role in reduced sensitivity to praziquantel. J Bioenerg Biomembr. 2020Oct;52(5):397–408. PubMed PMID: 32557343; eng.
   PubMed Web of Science ®Google Scholar
• Sanchez MC, Cupit PM, Bu L, et al. Transcriptomic analysis of reduced sensitivity to praziquantel in Schistosoma mansoni. Mol Biochem Parasitol. 2019 Mar;228:6–15. PubMed PMID: 30658180; PubMed Central PMCID: PMCPMC6372308. eng
   PubMed Web of Science ®Google Scholar
• Botros SS, Bennett JL. Praziquantel resistance. Expert Opin Drug Discov. 2007Oct;2(s1):S35–40. PubMed PMID: 23489031; eng.
   PubMedGoogle Scholar
• Appleton CC, Mbaye A. Praziquantel–quality, dosages and markers of resistance. PubMed PMID: 11685889. Trends Parasitol. 2001 Aug;17(8):356–357.
   PubMedGoogle Scholar
• Guo Y, Chen B, Chen LJ, et al. Current status and future prospects of mesenchymal stem cell therapy for liver fibrosis. J Zhejiang Univ Sci B. 2016Nov;1711:831–841. PubMed PMID: 27819130; PubMed Central PMCID: PMCPMC5120225
   PubMed Web of Science ®Google Scholar
• Papp V, Rokusz A, Dezso K, et al. Expansion of hepatic stem cell compartment boosts liver regeneration. Stem Cells Dev. 2014 Jan 1;23(1):56–65. PubMed PMID: 23952741; PubMed Central PMCID: PMCPMC3870598.
   PubMed Web of Science ®Google Scholar
• Puppi J, Strom SC, Hughes RD, et al. Improving the techniques for human hepatocyte transplantation: report from a consensus meeting in London. Cell Transplant. 2012;21(1):1–10. PubMed PMID: 21457616.
   PubMed Web of Science ®Google Scholar
• Kharaziha P, Hellstrom PM, Noorinayer B, et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol. 2009Oct;2110:1199–1205. PubMed PMID: 19455046
   PubMed Web of Science ®Google Scholar
• Levicar N, Pai M, Habib NA, et al. Long-term clinical results of autologous infusion of mobilized adult bone marrow derived CD34+ cells in patients with chronic liver disease. Cell Prolif. 2008 Feb;41 Suppl 1:115–125. PubMed PMID: 18181952; PubMed Central PMCID: PMCPMC6496663
   PubMed Web of Science ®Google Scholar
• Tocci A, Forte L. Mesenchymal stem cell: use and perspectives. Hematol J. 2003;4(2):92–96. PubMed PMID: 12750726.
   PubMedGoogle Scholar
• Jung KH, Shin HP, Lee S, et al. Effect of human umbilical cord blood-derived mesenchymal stem cells in a cirrhotic rat model. Liver Int. 2009Jul;296:898–909. PubMed PMID: 19422480; eng
   PubMed Web of Science ®Google Scholar
• Elkhafif N, Voss B, Hammam O, et al. Homing of transplanted bone marrow cells in livers of Schistosoma mansoni-infected mice. APMIS. 2010Apr;1184:277–287. PubMed PMID: 20402673
   PubMed Web of Science ®Google Scholar
• Ismail HI, Farrag AK, Abo-Raya AA. Pygeum africanum as an inhibitor for fibrogenesis: does it have a role in experimental hepatic schistosomal granuloma. Egyp J Med Microbiol. 2001;10:533–542.
   Google Scholar
• Cho KA, Ju SY, Cho SJ, et al. Mesenchymal stem cells showed the highest potential for the regeneration of injured liver tissue compared with other subpopulations of the bone marrow. Cell Biol Int. 2009Jul;337:772–777. PubMed PMID: 19427913
   PubMed Web of Science ®Google Scholar
• Reddy NP, Vemuri MC, Pallu R. Isolation of stem cells from human umbilical cord blood. Methods Mol Biol. 2007;407:149–163. PubMed PMID: 18453255; eng.
   PubMedGoogle Scholar
• Khalifa YH, Mourad GM, Stephanos WM, et al. Bone marrow-derived mesenchymal stem cell potential regression of dysplasia associating experimental liver fibrosis in albino rats. Biomed Res Int. 2019;2019:5376165. PubMed PMID: 31781620; PubMed Central PMCID: PMCPMC6874956. eng.
   PubMedGoogle Scholar
• Starc N, Ingo D, Conforti A, et al. Biological and functional characterization of bone marrow-derived mesenchymal stromal cells from patients affected by primary immunodeficiency. Sci Rep. 2017 Aug 15;7(1):8153. PubMed PMID: 28811575; PubMed Central PMCID: PMCPMC5557950. eng.
   PubMedGoogle Scholar
• Carotti S, Morini S, Corradini SG, et al. Glial fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic and posttransplant recurrent hepatitis C. Liver Transplant. 2008Jun;146:806–814. PubMed PMID: 18508359; eng
   PubMed Web of Science ®Google Scholar
• Darwish MA, Faris R, Darwish N, et al. Hepatitis c and cirrhotic liver disease in the Nile delta of Egypt: a community-based study. Am J Trop Med Hyg. 2001 Mar-Apr;643–4:147–153. PubMed PMID: 11442209.
   PubMed Web of Science ®Google Scholar
• Moodley Y, Atienza D, Manuelpillai U, et al. Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. Am J Pathol. 2009Jul;1751:303–313. PubMed PMID: 19497992; PubMed Central PMCID: PMCPMC2708816
   PubMed Web of Science ®Google Scholar
• Kucia M, Reca R, Jala VR, et al. Bone marrow as a home of heterogenous populations of nonhematopoietic stem cells. Leukemia. 2005Jul;197:1118–1127. PubMed PMID: 15902288; eng
   PubMed Web of Science ®Google Scholar
• Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy Position Statement Cytotherapy. 2006;8(4):315–317. PubMed PMID: 16923606; eng.
   Google Scholar
• Lee OK, Kuo TK, Chen WM, et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood. 2004 Mar 1;103(5):1669–1675. PubMed PMID: 14576065; eng.
   PubMed Web of Science ®Google Scholar
• Brooke G, Cook M, Blair C, et al. Therapeutic applications of mesenchymal stromal cells. Semin Cell Dev Biol. 2007Dec;186:846–858. PubMed PMID: 18024097; eng
   PubMed Web of Science ®Google Scholar
• D’Ippolito G, Schiller PC, Ricordi C, et al. Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow. J Bone Miner Res. 1999Jul;147:1115–1122. PubMed PMID: 10404011; eng
   PubMed Web of Science ®Google Scholar
• Coulson-Thomas VJ, Gesteira TF, Hascall V, et al. Umbilical cord mesenchymal stem cells suppress host rejection: the role of the glycocalyx. J Biol Chem. 2014 Aug 22;289(34):23465–23481. PubMed PMID: 24986866; PubMed Central PMCID: PMCPMC4156039. eng.
   PubMed Web of Science ®Google Scholar
• Kamel MM, Baz HGE, Demerdash Z, et al. Cord blood-derived mesenchymal stem cells with hepatogenic differentiation potential ameliorate chronic liver affection in experimental models. Adv Clin Exp Med. 2018Oct;2710:1329–1339. PubMed PMID: 30048056; eng
   PubMed Web of Science ®Google Scholar
• Hassan MM, Hwang LY, Hatten CJ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002Nov;365:1206–1213. PubMed PMID: 12395331
   PubMed Web of Science ®Google Scholar
• Abou-Zied AM, Soliman RH, Hefila SM, et al. Biochemical and Parasitological Studies on the Effect of hUCB-Selected CD34(+) Progenitor/Stem Cells in Mice Infected with Schistosoma mansoni. Int J Stem Cells. 2014Nov;72:98–107. PubMed PMID: 25473447; PubMed Central PMCID: PMCPMC4249909. eng
   PubMedGoogle Scholar
• Poynard T, Lebray P, Ingiliz P, et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol. 2010 Apr 22;10:40. PubMed PMID: 20412588; PubMed Central PMCID: PMCPMC2864202. eng.
   PubMed Web of Science ®Google Scholar
• Zhao DC, Lei JX, Chen R, et al. Bone marrow-derived mesenchymal stem cells protect against experimental liver fibrosis in rats. World J Gastroenterol. 2005 Jun 14;11(22):3431–3440. PubMed PMID: 15948250; PubMed Central PMCID: PMCPMC4315999. eng.
   PubMed Web of Science ®Google Scholar
• Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008 Mar 8;371(9615):838–851. PubMed PMID: 18328931; PubMed Central PMCID: PMCPMC2271178. eng.
   PubMed Web of Science ®Google Scholar
• Fagone P, Mangano K, Pesce A, et al. Emerging therapeutic targets for the treatment of hepatic fibrosis. Drug Discov Today. 2016Feb;212:369–375. PubMed PMID: 26523773; eng
   PubMed Web of Science ®Google Scholar
• Fagone P, Mangano K, Mammana S, et al. Identification of novel targets for the diagnosis and treatment of liver fibrosis. Int J Mol Med. 2015Sep;363:747–752. PubMed PMID: 26135677; eng
   PubMed Web of Science ®Google Scholar
• Eng FJ, Friedman SL, Fibrogenesis I. New insights into hepatic stellate cell activation: the simple becomes complex. Am J Physiol Gastrointest Liver Physiol. 2000Jul;279(1):G7–g11. PubMed PMID: 10898741; eng.
   PubMed Web of Science ®Google Scholar
• Tsukada S, Parsons CJ, Rippe RA. Mechanisms of liver fibrosis. Clin Chim Acta. 2006Feb;364(1–2):33–60. PubMed PMID: 16139830; eng.
   PubMed Web of Science ®Google Scholar
• Chang YJ, Liu JW, Lin PC, et al. Mesenchymal stem cells facilitate recovery from chemically induced liver damage and decrease liver fibrosis. Life Sci. 2009 Sep 23;85(13–14):517–525. PubMed PMID: 19686763; eng.
   PubMed Web of Science ®Google Scholar
• Ozaki I, Zhao G, Mizuta T, et al. Hepatocyte growth factor induces collagenase (matrix metalloproteinase-1) via the transcription factor Ets-1 in human hepatic stellate cell line. J Hepatol. 2002Feb;362:169–178. PubMed PMID: 11830328; eng
   PubMed Web of Science ®Google Scholar
• Zhang B, Inagaki M, Jiang B, et al. Effects of bone marrow and hepatocyte transplantation on liver injury. J Surg Res. 2009Nov;1571:71–80. PubMed PMID: 19345373; eng
   PubMed Web of Science ®Google Scholar
• Muddu AK, Guha IN, Elsharkawy AM, et al. Resolving fibrosis in the diseased liver: translating the scientific promise to the clinic. Int J Biochem Cell Biol. 2007;39(4):695–714. PubMed PMID: 17110155; eng.
   PubMed Web of Science ®Google Scholar
• Li LC, Li J, Gao J. Functions of galectin-3 and its role in fibrotic diseases. J Pharmacol Exp Ther. 2014Nov;351(2):336–343. PubMed PMID: 25194021; eng.
   PubMed Web of Science ®Google Scholar
• Pellicoro A, Ramachandran P, Iredale JP, et al. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol. 2014Mar;143:181–194. PubMed PMID: 24566915; eng
   PubMed Web of Science ®Google Scholar
• Imamura M, Ogawa T, Sasaguri Y, et al. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology. 2005Jan;1281:138–146. PubMed PMID: 15633130; eng
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang FS. Stem cell therapies for liver failure and cirrhosis. J Hepatol. 2013Jul;59(1):183–185. PubMed PMID: 23353868; eng.
   PubMed Web of Science ®Google Scholar
• Li J, Li M, Niu B, et al. Therapeutic potential of stem cell in liver regeneration. Front Med. 2011Mar;51:26–32. PubMed PMID: 21681671; eng
   PubMedGoogle Scholar
• Liu J, Liu Q, Chen X. The Immunomodulatory Effects of Mesenchymal Stem Cells on Regulatory B Cells. Front Immunol. 2020;11:1843. PubMed PMID: 32922398; PubMed Central PMCID: PMCPMC7456948. eng.
   PubMed Web of Science ®Google Scholar
• Franquesa M, Hoogduijn MJ, Bestard O, et al. Immunomodulatory effect of mesenchymal stem cells on B cells. Front Immunol. 2012;3:212. PubMed PMID: 22833744; PubMed Central PMCID: PMCPMC3400888. eng.
   PubMed Web of Science ®Google Scholar
• Chiaramonte MG, Donaldson DD, Cheever AW, et al. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest. 1999Sep;1046:777–785. PubMed PMID: 10491413; PubMed Central PMCID: PMCPMC408441. eng
   PubMed Web of Science ®Google Scholar
• Safadi R, Ohta M, Alvarez CE, et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology. 2004Sep;1273:870–882. PubMed PMID: 15362042; eng
   PubMed Web of Science ®Google Scholar
• Lo Sicco C, Reverberi D, Balbi C, et al. Mesenchymal stem cell-derived extracellular vesicles as mediators of anti-inflammatory effects: endorsement of macrophage polarization. Stem Cells Transl Med. 2017Mar;63:1018–1028. PubMed PMID: 28186708; PubMed Central PMCID: PMCPMC5442783. eng
   PubMed Web of Science ®Google Scholar
• Zhu M, Hua T, Ouyang T, et al. Applications of mesenchymal stem cells in liver fibrosis: novel strategies, mechanisms, and clinical practice. Stem Cells Int. 2021;2021:6546780. PubMed PMID: 34434239; PubMed Central PMCID: PMCPMC8380491. eng.
   PubMed Web of Science ®Google Scholar
• Parekkadan B, van Poll D, Megeed Z, et al. Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells. Biochem Biophys Res Commun. 2007 Nov 16;363(2):247–252. PubMed PMID: 17869217; PubMed Central PMCID: PMCPMC2096777. eng.
   PubMed Web of Science ®Google Scholar
• Hu C, Zhao L, Zhang L, et al. Mesenchymal stem cell-based cell-free strategies: safe and effective treatments for liver injury. Stem Cell Res Ther. 2020 Sep 3;11(1):377. PubMed PMID: 32883343; PubMed Central PMCID: PMCPMC7469278. eng.
   PubMed Web of Science ®Google Scholar
• Chang D, Ramalho LN, Ramalho FS, et al. Hepatic stellate cells in human schistosomiasis mansoni: a comparative immunohistochemical study with liver cirrhosis. Acta Trop. 2006Mar;973:318–323. PubMed PMID: 16473318; eng
   PubMed Web of Science ®Google Scholar
• Eissa M, Elarabany N, Hyder A. In vitro efficacy of liver microenvironment in bone marrow mesenchymal stem cell differentiation. Vitro Cell Dev Biol Anim. 2020Apr;56(4):341–348. PubMed PMID: 32270392; eng.
   PubMed Web of Science ®Google Scholar
• Zhou X, Cui L, Zhou X, et al. Induction of hepatocyte-like cells from human umbilical cord-derived mesenchymal stem cells by defined microRNAs. J Cell Mol Med. 2017May;215:881–893. PubMed PMID: 27874233; PubMed Central PMCID: PMCPMC5387126. eng
   PubMed Web of Science ®Google Scholar
• Lyra AC, Soares MB, da Silva LF, et al. Infusion of autologous bone marrow mononuclear cells through hepatic artery results in a short-term improvement of liver function in patients with chronic liver disease: a pilot randomized controlled study. Eur J Gastroenterol Hepatol. 2010Jan;221:33–42. PubMed PMID: 19654548
   PubMed Web of Science ®Google Scholar
• Spahr L, Chalandon Y, Terraz S, et al. Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial. PLoS One. 2013;8(1):e53719. PubMed PMID: 23341981; PubMed Central PMCID: PMCPMC3544843.
   PubMed Web of Science ®Google Scholar
• Yannaki E, Anagnostopoulos A, Kapetanos D, et al. Lasting amelioration in the clinical course of decompensated alcoholic cirrhosis with boost infusions of mobilized peripheral blood stem cells. Exp Hematol. 2006Nov;3411:1583–1587. PubMed PMID: 17046578
   PubMed Web of Science ®Google Scholar
• El-Ansary M, Abdel-Aziz I, Mogawer S, et al. Phase II trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis. Stem Cell Rev Rep. 2012Sep;83:972–981. PubMed PMID: 21989829
   PubMed Web of Science ®Google Scholar
• Peng L, Xie DY, Lin BL, et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology. 2011 Sep 2;54(3):820–828. PubMed PMID: 21608000.
   PubMed Web of Science ®Google Scholar
• Mohamadnejad M, Alimoghaddam K, Bagheri M, et al. Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis. Liver Int. 2013Nov;3310:1490–1496. PubMed PMID: 23763455
   PubMed Web of Science ®Google Scholar
• Salama H, Zekri AR, Bahnassy AA, et al. Autologous CD34+ and CD133+ stem cells transplantation in patients with end stage liver disease. World J Gastroenterol. 2010 Nov 14;16(42):5297–5305. PubMed PMID: 21072892; PubMed Central PMCID: PMCPMC2980678.
   PubMed Web of Science ®Google Scholar
• Carvalho AB, Quintanilha LF, Dias JV. Bone marrow multipotent mesenchymal stromal cells do not reduce fibrosis or improve function in a rat model of severe chronic liver injury. Stem cells. 2008 ;26(5): 1307–1314. doi:10.1634/stemcells.2007-0941. PubMed PMID: 18308943; eng.
   PubMed Web of Science ®Google Scholar